Targeting GLP-1 receptor trafficking to improve agonist efficacy

B Jones; T Buenaventura; N Kanda; P Chabosseau; BM Owen; R Scott; R Goldin; N Angkathunyakul; IR Corrêa; Domenico Bosco; PR Johnson; L Piemonti; P Marchetti; AMJ Shapiro; BJ Cochran; AC Hanyaloglu; A Inoue; T Tan; GA Rutter; A Tomas; SR Bloom

doi:10.1038/s41467-018-03941-2

Targeting GLP-1 receptor trafficking to improve agonist efficacy

B Jones, T Buenaventura, N Kanda, P Chabosseau, BM Owen, R Scott, R Goldin, N Angkathunyakul, IR Corrêa, Domenico Bosco, PR Johnson, L Piemonti, P Marchetti, AMJ Shapiro, BJ Cochran, AC Hanyaloglu, A Inoue, T Tan, GA Rutter, A TomasSR Bloom

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D). Like other G protein-coupled receptors, the GLP-1R undergoes agonist-mediated endocytosis, but the functional and therapeutic consequences of modulating GLP-1R endocytic trafficking have not been clearly defined. Here, we investigate a series of biased GLP-1R agonists with variable propensities for GLP-1R internalization and recycling. Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in β-arrestin recruitment and faster agonist dissociation rates. Such molecules elicit glycemic benefits in mice without concomitant increases in signs of nausea, a common side effect of GLP-1 therapies. Our study identifies a set of agents with specific GLP-1R trafficking profiles and the potential for greater efficacy and tolerability as T2D treatments. © 2018 The Author(s).

Original language	English
Article number	1602
Journal	Nature Communications
Volume	9
Issue number	11
DOIs	https://doi.org/10.1038/s41467-018-03941-2
Publication status	Published - 2018

Access to Document

10.1038/s41467-018-03941-2

http://www.scopus.com/inward/record.url?scp=85046005577&partnerID=8YFLogxK

Cite this

Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, BM., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa, IR., Bosco, D., Johnson, PR., Piemonti, L., Marchetti, P., Shapiro, AMJ., Cochran, BJ., Hanyaloglu, AC., Inoue, A., Tan, T., Rutter, GA., ... Bloom, SR. (2018). Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nature Communications, 9(11), [1602]. https://doi.org/10.1038/s41467-018-03941-2

Targeting GLP-1 receptor trafficking to improve agonist efficacy. / Jones, B; Buenaventura, T; Kanda, N; Chabosseau, P; Owen, BM; Scott, R; Goldin, R; Angkathunyakul, N; Corrêa, IR; Bosco, Domenico; Johnson, PR; Piemonti, L; Marchetti, P; Shapiro, AMJ; Cochran, BJ; Hanyaloglu, AC; Inoue, A; Tan, T; Rutter, GA; Tomas, A; Bloom, SR.

In: Nature Communications, Vol. 9, No. 11, 1602, 2018.

Research output: Contribution to journal › Article › peer-review

Jones, B, Buenaventura, T, Kanda, N, Chabosseau, P, Owen, BM, Scott, R, Goldin, R, Angkathunyakul, N, Corrêa, IR, Bosco, D, Johnson, PR, Piemonti, L, Marchetti, P, Shapiro, AMJ, Cochran, BJ, Hanyaloglu, AC, Inoue, A, Tan, T, Rutter, GA, Tomas, A & Bloom, SR 2018, 'Targeting GLP-1 receptor trafficking to improve agonist efficacy', Nature Communications, vol. 9, no. 11, 1602. https://doi.org/10.1038/s41467-018-03941-2

Jones, B ; Buenaventura, T ; Kanda, N ; Chabosseau, P ; Owen, BM ; Scott, R ; Goldin, R ; Angkathunyakul, N ; Corrêa, IR ; Bosco, Domenico ; Johnson, PR ; Piemonti, L ; Marchetti, P ; Shapiro, AMJ ; Cochran, BJ ; Hanyaloglu, AC ; Inoue, A ; Tan, T ; Rutter, GA ; Tomas, A ; Bloom, SR. / Targeting GLP-1 receptor trafficking to improve agonist efficacy. In: Nature Communications. 2018 ; Vol. 9, No. 11.

@article{149f1d916f204444a8ca1e1b48c721ed,

title = "Targeting GLP-1 receptor trafficking to improve agonist efficacy",

abstract = "Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D). Like other G protein-coupled receptors, the GLP-1R undergoes agonist-mediated endocytosis, but the functional and therapeutic consequences of modulating GLP-1R endocytic trafficking have not been clearly defined. Here, we investigate a series of biased GLP-1R agonists with variable propensities for GLP-1R internalization and recycling. Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in β-arrestin recruitment and faster agonist dissociation rates. Such molecules elicit glycemic benefits in mice without concomitant increases in signs of nausea, a common side effect of GLP-1 therapies. Our study identifies a set of agents with specific GLP-1R trafficking profiles and the potential for greater efficacy and tolerability as T2D treatments. {\textcopyright} 2018 The Author(s).",

author = "B Jones and T Buenaventura and N Kanda and P Chabosseau and BM Owen and R Scott and R Goldin and N Angkathunyakul and IR Corr{\^e}a and Domenico Bosco and PR Johnson and L Piemonti and P Marchetti and AMJ Shapiro and BJ Cochran and AC Hanyaloglu and A Inoue and T Tan and GA Rutter and A Tomas and SR Bloom",

year = "2018",

doi = "10.1038/s41467-018-03941-2",

language = "English",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "NLM (Medline)",

number = "11",

}

TY - JOUR

T1 - Targeting GLP-1 receptor trafficking to improve agonist efficacy

AU - Jones, B

AU - Buenaventura, T

AU - Kanda, N

AU - Chabosseau, P

AU - Owen, BM

AU - Scott, R

AU - Goldin, R

AU - Angkathunyakul, N

AU - Corrêa, IR

AU - Bosco, Domenico

AU - Johnson, PR

AU - Piemonti, L

AU - Marchetti, P

AU - Shapiro, AMJ

AU - Cochran, BJ

AU - Hanyaloglu, AC

AU - Inoue, A

AU - Tan, T

AU - Rutter, GA

AU - Tomas, A

AU - Bloom, SR

PY - 2018

Y1 - 2018

N2 - Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D). Like other G protein-coupled receptors, the GLP-1R undergoes agonist-mediated endocytosis, but the functional and therapeutic consequences of modulating GLP-1R endocytic trafficking have not been clearly defined. Here, we investigate a series of biased GLP-1R agonists with variable propensities for GLP-1R internalization and recycling. Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in β-arrestin recruitment and faster agonist dissociation rates. Such molecules elicit glycemic benefits in mice without concomitant increases in signs of nausea, a common side effect of GLP-1 therapies. Our study identifies a set of agents with specific GLP-1R trafficking profiles and the potential for greater efficacy and tolerability as T2D treatments. © 2018 The Author(s).

AB - Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D). Like other G protein-coupled receptors, the GLP-1R undergoes agonist-mediated endocytosis, but the functional and therapeutic consequences of modulating GLP-1R endocytic trafficking have not been clearly defined. Here, we investigate a series of biased GLP-1R agonists with variable propensities for GLP-1R internalization and recycling. Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in β-arrestin recruitment and faster agonist dissociation rates. Such molecules elicit glycemic benefits in mice without concomitant increases in signs of nausea, a common side effect of GLP-1 therapies. Our study identifies a set of agents with specific GLP-1R trafficking profiles and the potential for greater efficacy and tolerability as T2D treatments. © 2018 The Author(s).

U2 - 10.1038/s41467-018-03941-2

DO - 10.1038/s41467-018-03941-2

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 11

M1 - 1602

ER -

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Abstract

Access to Document

Fingerprint

Cite this